<DOC>
	<DOCNO>NCT01872923</DOCNO>
	<brief_summary>The primary goal extension study investigate tolerability efficacy phase I set order see whether low dos initial study dose 0.25 mg/kg bw Amphinex Amphinex-based PCI bleomycin show comparable improve safety tolerability profile combination comparable sign efficacy .</brief_summary>
	<brief_title>Dose Escalating Study Amphinex-based PCI Bleomycin .</brief_title>
	<detailed_description>Use Amphinex enhancement Bleomycin intracellular target . The photosensitizer Amphinex activate Laser Light 652 nm . Superficial lesion ( cutaneous subcutaneous ) treat laser light administration Amphinex Bleomycin accord time schedule provide . Safety preliminary effect data evaluate low dose explore preceeding dose escalate study Amphinex .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<criteria>â€¢ Male female age 18 year give write informed consent Skin type I IV accord Fitzpatrick skin classification ( see Appendix G ) With diagnosis local recurrence advanced/metastatic , cutaneous subcutaneous malignancy Lesion measurement must do 2 week begin treatment . More one field lesion illuminate , care must take avoid overlap field illuminate Have discontinue investigational therapy radiotherapy least 2 week prior administration Amphinex baseline visit , recover acute effect therapy Have discontinue cytostatic cytotoxic therapy least 6 half life cycle agent prior administration Amphinex baseline visit Have performance status 02 Eastern Cooperative Oncology Group ( ECOG ) Scale ( see Appendix D ) Clinically assess eligible bleomycin chemotherapy Have predict life expectancy least 3 month Geographic proximity allow adequate followup If female : childbearing potential either terminate surgery , radiation , menopause attenuate use approve contraceptive method 3 month trial If male : reproductive potential either terminate attenuated use approve contraceptive method 3 month trial . Have receive prior PCI Tumours known erode major blood vessel adjacent illumination site Planned surgery first 28 day treatment , except plan surgical removal treat lesion Planned dentist appointment first 28 day treatment Anticancer therapy within first 28 day treatment Therapy drug induce light sensitivity ( e.g . tetracycline , sulfonamide , phenothiazine , sulfonylurea , hypoglycemic agent , thiazide diuretic , griseofulvin ) within first 14 day treatment Coexisting ophthalmic disease likely require slitlamp examination within first 28 day treatment History hypersensitivity/anaphylactic reaction Previous cumulative dose Bleomycin receive 200 000 IE Known allergy sensitivity photosensitisers Known allergy Cremophor Known allergy bleomycin Conditions contraindicate bleomycin treatment ( lung infection , impaired pulmonary function ) Conditions worsen expose light ( include porphyria ) Conditions associate risk poor protocol compliance Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Amphinex</keyword>
	<keyword>PCI</keyword>
	<keyword>Bleomycin</keyword>
	<keyword>Cutaneous malignancy</keyword>
	<keyword>Sub-cutaneous malignancy</keyword>
	<keyword>Safety</keyword>
	<keyword>Phase I</keyword>
	<keyword>Photochemical Internalisation</keyword>
	<keyword>Squamous Cell Carcinoma</keyword>
	<keyword>Head Neck cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>HNSCC</keyword>
	<keyword>SCCHN</keyword>
	<keyword>Advanced metastatic cancer</keyword>
	<keyword>Dose find</keyword>
</DOC>